XOLAIR® is a renowned brand that offers a self-administered treatment for allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. For patients ages 6 and above with moderate to severe asthma and sensitivity to a perennial aeroallergen, XOLAIR provides relief when symptoms are uncontrolled on inhaled corticosteroids (ICS). Additionally, XOLAIR is suitable for patients ages 12 and above who remain symptomatic despite H1 antihistamine treatment for chronic spontaneous urticaria.

Adult patients ages 18 and above with chronic rhinosinusitis and nasal polyps can benefit from XOLAIR as an add-on maintenance treatment if they have an inadequate response to nasal corticosteroids. XOLAIR helps open a world of possibilities for appropriate patients. To further assist patients, XOLAIR provides resources ranging from condition understanding to financial support.

With XOLAIR, patients can find the support they need to manage their conditions effectively and improve their quality of life